Retinoic acid receptor agonists - Pipeline Insight, 2024

This “Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Retinoic Acid Receptor (RARs) Agonist Understanding

Retinoic Acid Receptor (RARs) Agonist: Overview

Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RARa, RARß, and RAR?) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into m RNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of leads against breast, lung and prostate cancer orleukemia.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs Chapters

This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinoic Acid Receptor (RARs) Agonist Emerging Drugs

Palovarotene: Clementia Pharmaceuticals (Ipsen)Palovarotene is a RAR? agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.

IRX 5183: Allergan (AbbVie)IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RARa) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.

Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Retinoic Acid Receptor (RARs) Agonist

There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinoic Acid Receptor (RARs) Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.

Retinoic Acid Receptor (RARs) Agonist Report Insights

• Retinoic Acid Receptor (RARs) Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Retinoic Acid Receptor (RARs) Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Retinoic Acid Receptor (RARs) Agonist drugs?
• How many Retinoic Acid Receptor (RARs) Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Retinoic Acid Receptor (RARs) Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Retinoic Acid Receptor (RARs) Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Retinoic Acid Receptor (RARs) Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Clementia Pharmaceuticals (Ipsen)
• Nippon Shinyaku
• Bausch Health Companies
• Galderma
• Avecho Biotechnology
• Allergan (AbbVie)
• Celgene
• Sci TechDevelopment
• Polaryx Therapeutics

Key Products

• Palovarotene
• Tamibarotene
• IDP 126
• CD-5789
• Tretinoin topical
• IRX 5183
• Cintirorgon
• Fenretinide intravenous
• PLX-200

This product will be delivered within 2 business days.